News | April 02, 2015

CoreValve Transcatheter Valve Approved in Japan

Device found to improve heart failure class, all-cause mortality in more than 90 percent of Japanese patients

Medtronic, CoreValve, Japan, approval, trial

April 2, 2015 — Medtronic announced Japanese regulatory approval for the self-expanding transcatheter CoreValve system for patients with severe aortic stenosis (AS). Japanese regulatory authorities granted approval of the CoreValve system for transcatheter aortic valve implantation (TAVI) based on data from the CoreValve U.S. Pivotal Trials and the Medtronic CoreValve Japan Trial, which is the first study to evaluate a self-expandable transcatheter valve in the Japanese patient population.

“We are excited to be able to offer this new option for our patients, as the CoreValve system has demonstrated exceptional clinical results in studies globally as well as in Japan,” said Yoshiki Sawa, M.D., professor in the Department of Cardiovascular Surgery at Osaka University Graduate School of Medicine in Osaka, Japan. “Physicians in Japan should have confidence in making TAVI treatment decisions for patients who may benefit from a less invasive valve replacement procedure with this proven self-expandable valve.”

Data from the Extreme and High Risk Studies in the CoreValve U.S. Pivotal Trial demonstrated that the CoreValve system is safe and effective with high rates of survival and some of the lowest rates of stroke and valve leakage reported. Featuring a supra-annular valve design, the system has also achieved hemodynamics post-implant with results similar to the gold standard, surgical valves.

The Medtronic CoreValve Japan Trial confirmed the performance of CoreValve shown in the U.S. Pivotal Trial. At 6 months, 91.7 percent of the transfemoral patients in the Japan trial met the primary endpoint of improvement of at least one New York Heart Association class and aortic valve area greater than 1.2 cm2. For all patients in the trial, freedom from all-cause mortality at 6 months was 90.8 percent. The trial also demonstrated functional and anatomical effectiveness of CoreValve.

The CoreValve self-expanding nitinol frame enables physicians to deliver the device to the diseased valve in a controlled manner, allowing for accurate placement. Valves are delivered via the smallest (18Fr, or approximately 1/4 inch) TAVR delivery system available, making it possible to treat patients with difficult or small vasculature.

The device is indicated for patients with severe AS unable to undergo surgery, and for whom treatment with the CoreValve is determined to be the best option.

For more information: www.medtronic.com


Related Content

News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
Subscribe Now